Life Sciences

AWS Digital Therapeutics Whitepaper

Issue link:

Contents of this Issue


Page 1 of 9

D igital therapeutics are becoming an increasingly important tool for how life sciences companies bring products to market. Investors and pharma companies alike are entering the sector, attracted by mounting evidence that digital technologies drive clinically meaningful improvements in patient outcomes. New entrants, like the pioneers before them, are learning patient-facing digital therapeutics are only part of the solution in supporting the patient journey. To succeed, companies also need a secure, scalable and interoperable system for handling large volumes of potentially sensitive patient data. The amount of data generated from biosensors, wearables and mobile devices will continue to accelerate. The definition of digital therapeutics encompasses several subcategories. Smart pills and connected inhalers support pharmacological interventions by improving adherence and generating insights into patient behavior. Companion apps leverage mobile technology to enhance the patient experience through coaching, feedback on their condition, and actionable insights. Researchers have validated the effectiveness of such interventions. A randomized clinical trial of Propeller Health's digital health platform for asthma and COPD linked the combination to a significant drop in use of short-acting b-agonists and improved asthma control. 1 Standalone digital therapeutics can improve health outcomes independently of drug regimens. Researchers found that Omada Health's product reduced the risk of type 2 diabetes by 30%. 2 Akili Interactive won FDA approval for its therapeutic video game by showing children with ADHD had improved sustained attention and inhibitory control after four weeks of use. 3,4 DIGITAL THERAPEUTICS: HOW CLOUD TECHNOLOGY IS ENHANCING PATIENT EXPERIENCE AND OUTCOMES 2 OCTOBER 2020 PRESENTED BY: PUBLISHED BY:

Articles in this issue

view archives of Life Sciences - AWS Digital Therapeutics Whitepaper